GLSI: Bullish Pennant detected on 5 Oct 2026

GLSI is forming a bullish pennant pattern at $16.98 with excellent structure quality (15.0/15 score). The consolidation sits between key support at $14.25 and resistance at $20.31. While breakout quality scores strongly (11.0/13), volume confirmation is moderate (9.0/12), though current volume of 175,417 shares exceeds the 20-day average by 46%. The pattern has a 66.27% win probability with an overall quality score of 78.0/98. RSI at 48.24 shows neutral momentum—neither overbought nor oversold—providing room for directional expansion. The stock sits 118% above its 52-week low but 50% below its 52-week high, suggesting continued recovery potential.

GLSI is a clinical-stage biotechnology company developing the cancer immunotherapy nelipepimut-S (GLSI-100). The company presented Phase 3 FLAMINGO-01 results at AACR 2026, and received regulatory approval to expand FLAMINGO-01 into the U.K. HC Wainwright raised its price target to $69 from $50 in July 2026 with a Buy rating, though analyst sentiment is mixed with other downgrades to Sell, resulting in an overall consensus Hold rating. The company reported a quarterly loss of $0.27 per share, better than the $0.33 consensus estimate. Short interest is currently at the second-largest on record, though borrowing costs have declined to below 20%, contrasting with triple-digit rates when short interest peaked in December. Recent insider activity shows purchases of 5,800 shares over the last three months valued at $76,618.

A successful breakout above $20.31 resistance would target $17.92 conservatively (based on pennant geometry), with the pattern structure suggesting potential for continued upside if volume sustains above current levels. Invalidation occurs below $14.25 support. The 66.27% win probability indicates roughly two-thirds of similar patterns extend beyond resistance, supporting the bullish thesis. The pattern suggests traders should watch for volume confirmation above the average (120,475 shares) as price approaches the pennant apex—breakout conviction strengthens on elevated turnover. The relatively tight consolidation with neutral RSI positioning provides a clean risk/reward framework.

Elevated short interest at the second-largest on record presents volatility risk, though borrowing costs have collapsed to below 20% from triple-digit rates, potentially reducing short-squeeze catalysts. The stock remains below its 200-day moving average of $20.84 despite recent strength, indicating longer-term downtrend risk. Beta of 1.31 with volatility of 85.38% amplifies swing magnitude—moves may be more violent than broader markets. The biotech sector regime is bearish (-0.23 regime score), creating headwind regardless of company-specific catalysts. Critical risk: the FLAMINGO-01 Phase 3 trial remains ongoing with no definitive efficacy readout confirmed; any interim analysis disappointment could trigger sharp selloff. Recent 3-month performance is -16.93%, suggesting momentum skepticism.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.